Literatura académica sobre el tema "APR-246"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "APR-246".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "APR-246"
Jonsson-Videsater, Kerstin, Dina Ali, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul y Soren Lehmann. "In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs." Blood 114, n.º 22 (20 de noviembre de 2009): 2751. http://dx.doi.org/10.1182/blood.v114.22.2751.2751.
Texto completoCeder, Anna Sophia, Sofi E. Eriksson, Emarndeena Haji Cheteh, Vladimir J. N. Bykov, Lars Abrahmsen y Klas G. Wiman. "Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14712-e14712. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14712.
Texto completoMüller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones et al. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma". Cancers 13, n.º 17 (5 de septiembre de 2021): 4476. http://dx.doi.org/10.3390/cancers13174476.
Texto completoHong, Yuheng, Tianyuan Ren, Xiaoxuan Wang, Kai Fu, Xianhuo Wang y Huilai Zhang. "APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma". Blood 138, Supplement 1 (5 de noviembre de 2021): 3521. http://dx.doi.org/10.1182/blood-2021-150582.
Texto completoSynnott, Naoise C., Alyson M. Murray, Norma O'Donovan, Michael J. Duffy y John Crown. "Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e14098-e14098. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14098.
Texto completoXin, Qian, Qinghong Ji, Ying Zhang, Weihong Ma, Baoqing Tian, Yanli Liu, Yunsong Chen et al. "Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer". Oxidative Medicine and Cellular Longevity 2022 (20 de junio de 2022): 1–17. http://dx.doi.org/10.1155/2022/1112987.
Texto completoMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Thomas Uhlin, Mats R. H. Linderholm y Klas G. Wiman. "Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer". Blood 116, n.º 21 (19 de noviembre de 2010): 1806. http://dx.doi.org/10.1182/blood.v116.21.1806.1806.
Texto completoVenkatesh, Divya, Judith Michels, Cailian Liu, Sadna Budhu, Mariam M. George, Lars Abrahmsen, Roberta Zappasodi, Jedd D. Wolchok y Taha Merghoub. "Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1291. http://dx.doi.org/10.1158/1538-7445.am2022-1291.
Texto completoNagourney, Adam J., Joshua B. Gipoor, Steven S. Evans, Paulo D’Amora, Max S. Duesberg, Paula J. Bernard, Federico Francisco y Robert A. Nagourney. "Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants". Genes 14, n.º 3 (19 de marzo de 2023): 747. http://dx.doi.org/10.3390/genes14030747.
Texto completoMacha, Shawn J., Balakrishna Koneru, Trevor Burrow, Charles Zhu, Dzmitry Savitski, Jonas Nance, Kristyn McCoy, Cody Eslinger y C. Patrick Reynolds. "Abstract 6228: APR-246, which restores p53 function, is highly active against alternative lengthening of telomere (ALT) cell lines and PDXs". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 6228. http://dx.doi.org/10.1158/1538-7445.am2022-6228.
Texto completoActas de conferencias sobre el tema "APR-246"
Hernandez, Ana, Codi Mai, Shady Tantawy, Mary Ayres, Zahid Siddik y Varsha Gandhi. "APR-246 induces ferroptosis and overcomes cisplatin resistance in ovarian cancer". En The MD Anderson Summer Experience 2022. The University of MD Anderson Cancer Center, 2022. http://dx.doi.org/10.52519/00007.
Texto completoVenkatesh, Divya, Judith Michels, Cailin Lu, Sadna Budhu, Mariam George, Ouathek Ouerfelli, Lars Abrahmsen, Roberta Zappasodi, Jedd Wolchok y Taha Merghoub. "903 APR-246 induces an increase in tumor immunogenicity in a p53 independent manner". En SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0903.
Texto completoFransson, Åsa, Daria Glaessgen, Jessica Alfredsson, Klas G. Wiman, Svetlana Bajalica Lagercrantz y Nina Mohell. "Abstract 1639: Strong synergy with APR-246 and DNA-damaging drugs in primary ovarian cancer cells". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1639.
Texto completoMohell, Nina, Åsa Fransson, Jessica Alfredsson, Mikael von Euler, Ulf Björklund y Lars Abrahmsen. "Abstract 2523: Strong synergistic effects with APR-246 and cisplatin in p53-mutant lung cancer cells". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2523.
Texto completoGhosh, Arnab, Judith Michel, Lauren Dong, Nathan Suek, Hong Zhong, Sadna Budhu, Olivier de Henau, Jedd Wolchok y Taha Merghoub. "Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4843.
Texto completoGhosh, Arnab, Judith Michel, Lauren Dong, Nathan Suek, Hong Zhong, Sadna Budhu, Olivier de Henau, Jedd Wolchok y Taha Merghoub. "Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4843.
Texto completoMohell, Nina, Jessica Alfredsson, Åsa Fransson, Vladimir Bykov, Mikael von Euler, Klas Wiman y Ulf Björklund. "Abstract 1801: APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin". En Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1801.
Texto completoMohell, Nina, Åsa Fransson, Jessica Alfredsson, Mikael von Euler, Ulf Björklund y Lars Abrahmsen. "Abstract 270: Synergistic effect with APR-246 and standard chemotherapy in small cell lung cancer cells carrying smoking-associated TP53 mutations". En Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-270.
Texto completoMohell, Nina, Jessica Alfredsson, Maria Uustalu, Åsa Fransson, Vladimir J. N. Bykov, Klas G. Wiman y Ulf Björklund. "Abstract 3448: Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients." En Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3448.
Texto completoSallman, David A., Amy DeZern, Kendra Sweet, David P. Steensma, Thomas Cluzeau, Mikkael Sekeres, Guillermo Garcia-Manero et al. "Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct068.
Texto completo